Literature DB >> 17360047

Arvanil and anandamide up-regulate CD36 expression in human peripheral blood mononuclear cells.

Anna Maria Malfitano1, Gokce Altay Toruner, Patrizia Gazzerro, Chiara Laezza, Seema Husain, Davide Eletto, Pierangelo Orlando, Luciano De Petrocellis, Alexandra Terskiy, Marvin Schwalb, Emilia Vitale, Maurizio Bifulco.   

Abstract

In this study we analysed the regulation of gene expression by arvanil and anandamide in human peripheral blood mononuclear cells (PBMCs) to clarify their immunosuppressive properties. PBMCs were activated, leading to CD36 down regulation, that was normalized by arvanil and anandamide. We used microarray technology to identify a regulatory pattern associated with cell proliferation in the presence of both substances. CD3-CD28 stimulated PBMCs showed a pattern of up-regulated and down-regulated genes after treatment with these substances. We selected and analysed several genes chosen by their function in the regulation of cell proliferation. We showed a transcriptional control of the CD36 gene by arvanil and anandamide associated with an increased protein expression, thus suggesting a possible role of CD36 in anandamide and arvanil anti-inflammatory pattern.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17360047     DOI: 10.1016/j.imlet.2007.02.004

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  2 in total

1.  Rimonabant (SR141716) exerts anti-proliferative and immunomodulatory effects in human peripheral blood mononuclear cells.

Authors:  A M Malfitano; C Laezza; S Pisanti; P Gazzerro; M Bifulco
Journal:  Br J Pharmacol       Date:  2007-12-24       Impact factor: 8.739

2.  Effects on immune cells of a new 1,8-naphthyridin-2-one derivative and its analogues as selective CB2 agonists: implications in multiple sclerosis.

Authors:  Anna Maria Malfitano; Chiara Laezza; Alba D'Alessandro; Claudio Procaccini; Giuseppe Saccomanni; Tiziano Tuccinardi; Clementina Manera; Marco Macchia; Giuseppe Matarese; Patrizia Gazzerro; Maurizio Bifulco
Journal:  PLoS One       Date:  2013-05-01       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.